MX2009007290A - Compuestos agonistas del receptor de la proteina 1 similar al glucagon. - Google Patents
Compuestos agonistas del receptor de la proteina 1 similar al glucagon.Info
- Publication number
- MX2009007290A MX2009007290A MX2009007290A MX2009007290A MX2009007290A MX 2009007290 A MX2009007290 A MX 2009007290A MX 2009007290 A MX2009007290 A MX 2009007290A MX 2009007290 A MX2009007290 A MX 2009007290A MX 2009007290 A MX2009007290 A MX 2009007290A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- glucagon
- receptor
- glp
- agonist compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87904807P | 2007-01-05 | 2007-01-05 | |
| US93983107P | 2007-05-23 | 2007-05-23 | |
| US94531907P | 2007-06-20 | 2007-06-20 | |
| PCT/IE2008/000001 WO2008081418A1 (en) | 2007-01-05 | 2008-01-07 | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007290A true MX2009007290A (es) | 2009-07-14 |
Family
ID=39313161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007290A MX2009007290A (es) | 2007-01-05 | 2008-01-07 | Compuestos agonistas del receptor de la proteina 1 similar al glucagon. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090098130A1 (enExample) |
| EP (1) | EP2118131A1 (enExample) |
| JP (2) | JP5009376B2 (enExample) |
| KR (2) | KR20120083510A (enExample) |
| AU (1) | AU2008203641B2 (enExample) |
| BR (1) | BRPI0806308A2 (enExample) |
| CA (1) | CA2674112A1 (enExample) |
| MX (1) | MX2009007290A (enExample) |
| NZ (1) | NZ577686A (enExample) |
| WO (1) | WO2008081418A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| WO2011080102A2 (en) * | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Glp-1 analogues and derivatives |
| CA2785410A1 (en) | 2009-12-23 | 2011-06-30 | Carlos F. Barbas, Iii | Tyrosine bioconjugation through aqueous ene-like reactions |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| WO2011163462A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| KR20130050966A (ko) | 2010-07-12 | 2013-05-16 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 다기능적 항체 접합체 |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| KR101767860B1 (ko) | 2010-08-20 | 2017-08-14 | 와이어쓰 엘엘씨 | 디자이너 골형성 단백질 |
| PH12013500873A1 (en) * | 2010-11-05 | 2013-06-03 | Covx Tech Ireland Limited | Anti-diabetic compounds |
| MX391293B (es) | 2011-06-10 | 2025-03-21 | Hanmi Science Co Ltd | DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS. |
| KR101577734B1 (ko) | 2011-06-17 | 2015-12-29 | 한미사이언스 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2793950A2 (en) * | 2011-12-20 | 2014-10-29 | Pfizer Inc | Improved processes for preparing peptide conjugates and linkers |
| CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
| CN104066438B (zh) | 2011-12-22 | 2015-09-23 | 辉瑞公司 | 抗糖尿病化合物 |
| EP3447071A1 (en) | 2012-01-09 | 2019-02-27 | Pfizer Healthcare Ireland | Mutant antibodies and conjugation thereof |
| AU2013276610A1 (en) * | 2012-06-14 | 2015-01-15 | Sanofi | Exendin-4 peptide analogues |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014052451A2 (en) * | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Insulin analog dimers |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| IN2015DN03795A (enExample) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| MX372833B (es) | 2012-11-06 | 2020-06-25 | Hanmi Pharm Co Tld | Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina. |
| LT2934567T (lt) * | 2012-12-21 | 2018-09-10 | Sanofi | Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai |
| BR112015023071A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Indiana Res & Tech Corp | conjugados de insulina-incretina |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609800A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物 |
| AR098614A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| ES2947409T3 (es) | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Profármacos de insulina a base de amida lipídica |
| CN108271356A (zh) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| UA126960C2 (uk) | 2014-12-30 | 2023-03-01 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CN105854000A (zh) | 2015-02-11 | 2016-08-17 | 杭州鸿运华宁生物医药工程有限公司 | 一种药用glp-1r抗体融合蛋白的稳定溶液制剂 |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198604A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists |
| CN108025041A (zh) | 2015-06-30 | 2018-05-11 | 韩美药品株式会社 | 胰高血糖素衍生物和包含其长效缀合物的组合物 |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| MY197023A (en) | 2015-12-23 | 2023-05-22 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| DK3398961T3 (da) | 2015-12-31 | 2022-08-22 | Hanmi Pharm Ind Co Ltd | Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor |
| TWI757305B (zh) | 2016-06-29 | 2022-03-11 | 南韓商韓美藥品股份有限公司 | 升糖素衍生物、其接合物、及包含其之組成物、及其醫療用途 |
| JOP20190177A1 (ar) * | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
| PE20200013A1 (es) * | 2017-06-20 | 2020-01-06 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 |
| MA49459A (fr) | 2017-06-21 | 2020-04-29 | Amgen Inc | Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1 |
| CN111410686B (zh) * | 2020-03-18 | 2021-02-26 | 南京枫璟生物医药科技有限公司 | Glp-1r激活剂的分子改构及其二聚体在治疗代谢病中的应用 |
| JP2024501467A (ja) * | 2020-12-11 | 2024-01-12 | アイピー２アイピーオー イノベ－ションズ リミテッド | 新規化合物 |
| JP2024507795A (ja) * | 2021-02-16 | 2024-02-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | グルカゴン様ペプチド－１受容体アンタゴニスト |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) * | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) * | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
| JPH05509294A (ja) * | 1990-04-06 | 1993-12-22 | ラ ホヤ キャンサー リサーチ ファウンデーション | 血栓症治療のための方法および組成物 |
| US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6080840A (en) * | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5733757A (en) * | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6326176B1 (en) * | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| WO2000070351A2 (en) * | 1999-05-14 | 2000-11-23 | Mcgill University | Protein-protein interactions and methods for identifying them |
| SI1180121T1 (en) * | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6294374B1 (en) * | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| HU230603B1 (hu) * | 2000-12-07 | 2017-03-28 | Eli Lilly And Company | GLP1 fúziós fehérjék |
| US20030045477A1 (en) * | 2001-07-26 | 2003-03-06 | Fortuna Haviv | Peptides having antiangiogenic activity |
| PL1641823T3 (pl) * | 2003-06-12 | 2012-02-29 | Lilly Co Eli | Białka fuzyjne analogu GLP-1 |
| ES2298785T3 (es) * | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
| JPWO2005015595A1 (ja) * | 2003-08-07 | 2006-10-05 | 富士通株式会社 | マイクロスイッチング素子およびその製造方法 |
| CN1893980A (zh) * | 2003-12-18 | 2007-01-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp－1类似物 |
| EP1797127B1 (en) * | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modified fc molecules |
| JP5167473B2 (ja) * | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| GB2427360A (en) * | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| KR101309948B1 (ko) * | 2006-11-10 | 2013-09-23 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| EP2650006A1 (en) * | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
-
2008
- 2008-01-04 US US11/969,850 patent/US20090098130A1/en not_active Abandoned
- 2008-01-07 JP JP2009544484A patent/JP5009376B2/ja not_active Expired - Fee Related
- 2008-01-07 AU AU2008203641A patent/AU2008203641B2/en not_active Ceased
- 2008-01-07 BR BRPI0806308-7A patent/BRPI0806308A2/pt not_active IP Right Cessation
- 2008-01-07 CA CA002674112A patent/CA2674112A1/en not_active Abandoned
- 2008-01-07 MX MX2009007290A patent/MX2009007290A/es active IP Right Grant
- 2008-01-07 EP EP08702600A patent/EP2118131A1/en not_active Withdrawn
- 2008-01-07 NZ NZ577686A patent/NZ577686A/en not_active IP Right Cessation
- 2008-01-07 KR KR1020127014446A patent/KR20120083510A/ko not_active Ceased
- 2008-01-07 WO PCT/IE2008/000001 patent/WO2008081418A1/en not_active Ceased
- 2008-01-07 KR KR1020097013938A patent/KR101224335B1/ko not_active Expired - Fee Related
-
2012
- 2012-04-10 JP JP2012089113A patent/JP2012184232A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120083510A (ko) | 2012-07-25 |
| JP5009376B2 (ja) | 2012-08-22 |
| WO2008081418A1 (en) | 2008-07-10 |
| JP2010514835A (ja) | 2010-05-06 |
| EP2118131A1 (en) | 2009-11-18 |
| AU2008203641A1 (en) | 2008-07-10 |
| KR20090096498A (ko) | 2009-09-10 |
| JP2012184232A (ja) | 2012-09-27 |
| NZ577686A (en) | 2011-11-25 |
| AU2008203641B2 (en) | 2011-10-06 |
| KR101224335B1 (ko) | 2013-01-25 |
| US20090098130A1 (en) | 2009-04-16 |
| BRPI0806308A2 (pt) | 2011-09-06 |
| CA2674112A1 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007290A (es) | Compuestos agonistas del receptor de la proteina 1 similar al glucagon. | |
| MX2009007145A (es) | Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable. | |
| WO2008064054A3 (en) | Compounds which modulate the cb2 receptor | |
| EP1993560A4 (en) | CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT | |
| NZ585131A (en) | Use melanocortins to treat insulin sensitivity | |
| MX2009008923A (es) | Compuestos y metodos para modular receptores acoplados por proteina g. | |
| MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
| ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
| MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
| MX2009005461A (es) | N-oxidos de analogos de 4,5-epoxi-morfinano. | |
| WO2009061652A8 (en) | Compounds which modulate the cb2 receptor | |
| MX2009002820A (es) | Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1. | |
| MX2009005045A (es) | Compuestos antiangiogenos. | |
| SG164369A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
| WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
| EP3838298A3 (en) | Psma binding ligand-linker conjugates and methods for using | |
| WO2008059370A8 (en) | Substituted bicyclocarboxyamide compounds | |
| WO2010064012A3 (en) | Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 ) | |
| PH12013500873A1 (en) | Anti-diabetic compounds | |
| WO2007131219A3 (en) | Cannabinoid receptor antagonists/inverse agonists | |
| MA29788B1 (fr) | Combinaisons comprenant un inhibiteur des recepteurs vegf | |
| MY146506A (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
| WO2008050199A3 (en) | Substituted phenylmethyl bicyclocarboxyamide compounds | |
| EP2195331A4 (en) | SYNTHETIC APOLIPOPROTEIN RECIPIENTS AND METHOD OF USE | |
| WO2010014258A3 (en) | Conjugates having a releasable linkage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |